VALLEY FORGE, Pa. A series of health-oriented newsletters from Good Neighbor Pharmacy’s Diabetes Shoppe program has garnered honors for its effectiveness at helping people living with diabetes manage their disease.

GNP is the retail service division and branding program operated by AmerisourceBergen for independent pharmacies. The Living Without Limits newsletters published by Diabetes Shoppe – a program offered to GNP members specializing in the care of patients with diabetes – were recently awarded four awards for patient education by the National Health Information Awards Program. Living Without Limits won in several categories. Among them: a Gold Series Award for the past year’s issues of Living Without Limits for Kids, a Silver Series Award for the past year’s issues of Living Without Limits, and Bronze awards on single issues for both Living Without Limits and Living Without Limits for Kids.

The awards program is organized by the Health Information Resource Center, a national clearinghouse for consumer health information programs and materials. Diabetes Shoppe was competing with more than 1,000 entries submitted by leading organizations in the consumer health field, according to GNP.

The Living Without Limits newsletters are distributed to GNP locations across the United States that offer diabetes counseling and specialized services through the Diabetes Shoppe program. The newsletters contain health information, recipes, and information specific to patients with diabetes.

GSK: Rheumatoid arthritis treatment meets trial goals

LONDON A late-stage clinical trial of a biotech drug for rheumatoid arthritis has met its goals, the drug’s developers announced Wednesday.

British drug maker GlaxoSmithKline and Danish drug maker Genmab announced that patients in a phase 3 trial taking ofatumumab experienced a 20% improvement in the number of swollen and tender joints, as the companies expected.

In the 260-patient study, the 129 patients taking ofatumumab had a 50% response rate, compared to 27% of those taking placebo. The companies also said there were no unexpected safety problems, but 5% of patients experienced rash, hives, throat irritation and other side effects.

“We have always believed in ofatumumab’s potential to make a difference in patients’ lives,” Genmab CEO Lisa Drakeman said in a statement. “We are pleased with the results of this study, supporting the further investigation of this antibody’s promise in the treatment of RA.”

RELATED NEWS

The workshops, sponsored by McKesson, have been offered by the Alexandria, Va.-based organization for more than 20 years and are slated to take place June 8-10 in Denver, Colo., and Oct. 4-6 in Boston.

Forgotten Password

Registration complete

REGISTER

USERNAME *

Spaces are allowed; punctuation is not allowed except for periods, hyphens, and underscores.

E-MAIL ADDRESS *

A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.

Password *

Confirm Password *

Please choose a password for your account; it must be 8 - 30 characters. .

First Name *

Last Name *

Company Name *

Job Title *

ZIP *

Country *

Are you a *

Retailer or Healthcare professional

Non-Retailer

How many stores do you operate?: *

Which best describes the business/industry you work in?: *

Which best describes your job title?: *

Please select the newsletters you would like to subscribe to

DSN A.M.
Daily news stories covering the retail drug industry

Breaking News
First-to-the-market with developing stories in the industry